Inherited long QT syndrome revealed by antifungals drug-drug interaction

Journal of Clinical Pharmacy and Therapeutics

Volumn 32, Issue 3, 2007, Pages 321-324

  Eiden, C ^a   Peyriere H ^a   Tichit, R ^b   Cociglio, M ^a   Amedro, P ^b   Blayac, J P ^a   Margueritte, G ^b   Hillaire Buys, D ^a  

^a LAPEYRONIE HOSPITAL   (France)

^b HÔPITAL ARNAUD DE VILLENEUVE   (France)

Author keywords

Drug interaction; QT interval prolongation; Risk factors; Voriconazole

Indexed keywords

AMIKACIN; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; MAGNESIUM; MAGNESIUM SULFATE; NADOLOL; PIPERACILLIN PLUS TAZOBACTAM; POSACONAZOLE; VANCOMYCIN; VORICONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ADD ON THERAPY; ADOLESCENT; ARTICLE; CASE REPORT; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; ELECTROCARDIOGRAM; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HEART ARREST; HOLTER MONITORING; HUMAN; HYPOMAGNESEMIA; INTENSIVE CARE; LONG QT SYNDROME; MUCORMYCOSIS; PALLOR; QT DISPERSION; TACHYCARDIA; TORSADE DES POINTES; TREATMENT DURATION;

ACUTE DISEASE; ADOLESCENT; ANTIBIOTICS, ANTIFUNGAL; ARYL HYDROCARBON HYDROXYLASES; FEMALE; GENOTYPE; HUMANS; INJECTIONS, INTRAVENOUS; LEUKEMIA, MYELOID; LONG QT SYNDROME; MIXED FUNCTION OXYGENASES; MUCORMYCOSIS; PYRIMIDINES; TORSADES DE POINTES; TRIAZOLES;

EID: 34247889989     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2007.00812.x     Document Type: Article

References (15)

1. Rosen GP, Nielsen K, Glenn S, Abelson J, Deville J, Moore TB (2005) Invasive fungal infections in pediatric oncology patients: 11-year experience at a single institution. Journal of Pediatric Hematology/Oncology, 27, 135 140.
2. Johnson LB, Kauffman CA (2003) Voriconazole: a new triazole antifungal agent. Clinical Infectious Diseases, 36, 630 637.
3. Boucher HW, Groll AH, Chiou CC, Walsh TJ (2004) Newer systemic antifungal agents: pharmacokinetics, safety and efficacy. Drugs, 64, 1997 2020.
4. Leveque D, Nivoix Y, Jehl F, Herbrecht R (2006) Clinical pharmacokinetics of voriconazole. International Journal of Antimicrobial Agents, 27, 274 284.
5. Lazarus HM, Blumer JL, Yanovich S, Schlamm H, Romero A (2002) Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. Journal of Clinical Pharmacology, 42, 395 402.
6. Tan K, Brayshaw N, Tomaszewski K, Troke P, Wood N (2006) Investigation ofthe potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. Journal of Clinical Pharmacology, 46, 235 243.
7. Alkan Y, Haefeli WE, Burhenne J, Stein J, Yaniv I, Shalit I (2004) Voriconazole-induced QT interval prolongation and ventricular tachycardia: a non-concentration-dependent adverse effect. Clinical Infectious Diseases, 39, e49 e52.
8. Owens RC (2004) QT prolongation with antimicrobial agents: understanding the significance. Drugs, 64, 1091 1124.
9. De Morais SM, Goldstein JA, Xie HG et al. (1995) Genetic analysis of the S-mephenytoin polymorphism in a Chinese population. Clinical Pharmacology and Therapeutics, 58, 404 411.
10. Naranjo CA, Busto U, Sellers EM et al. (1981) A method for estimating the probability of adverse drug reactions. Clinical Pharmacology and Therapeutics, 30, 239 245.
11. Gage R, Stopher DA (1998) A rapid HPLC assay for voriconazole in human plasma. Journal of Pharmaceutical and Biomedical Analysis, 17, 1449 1453.
12. Zeltser D, Justo D, Halkin A, Prokhorov V, Heller K, Viskin S (2003) Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors. Medicine, 82, 282 290.
13. Bagatell R, Hainstock M, Lowe MC, Barber BJ, Samson RA (2005) The perfect storm: Torsades de Pointes in a child with leukemia. Pediatric Blood & Cancer, DOI:.
14. Wood N, Tan K, Purkins L et al. (2003) Effect of omeprazole on the steady-state pharmacokinetics of voriconazole. British Journal of Clinical Pharmacology, 56 (Suppl.1 56 61.
15. Mikus G, Schowel V, Drzewinska M et al. (2006) Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir. Clinical Pharmacology and Therapeutics, 80, 126 135.